Tuesday, September 15, 2026

 

 

We're Turning into a More Innovative Company: Teva Pharmaceuticals CEO Richard Francis

(9/14, CNBC) ...Richard Francis, Teva Pharmaceuticals CEO short and pro, joins 'Power Lunch' to discuss the company's turnaround strategy, expanding its market access, its next growth leg, and more... Full

 

Teva CEO on Shares Trading Directly on the NYSE

(9/14, Bloomberg) ...Teva Pharmaceuticals President & CEO Richard Francis, discusses why Teva chose to make the change now and what will be different for investors as the shares move from ADRs to direct NYSE trading. He speaks with Romaine Bostick & Isabelle Lee on "The Close."... Sub. Req'd

 

Teva CEO on the Company's NYSE Debut and What's Next

(9/15, Yahoo! Finance) ...Teva Pharmaceuticals (TEVA) CEO Richard Francis joins Market Domination Overtime to discuss the company's NYSE debut and what's next for the pharmaceutical company... Full

 

Teva Pharmaceutical (NYSE: TEVA) Rings The Closing Bell®

(9/15, NYSE YouTube) ...The New York Stock Exchange welcomes Teva Pharmaceuticals (NYSE: TEVA) to the podium to celebrate their first day of trading ordinary shares. To honor the occasion, Richard Francis, President & CEO, will ring The Closing Bell®... Full

 

Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform

(9/15, MarketBeat) ...Teva Pharmaceutical Industries NYSE: TEVA CEO Richard Francis said the company has progressed from the initial phase of its "Pivot to Growth" plan into its next stage, citing momentum in branded medicines, innovation, generics and biosimilars, as well as improved financial flexibility... Full

 

Teva Transitions To Direct Listing On NYSE

(9/15, RTT News) ...The listing is expected to follow a transition from the company's American Depositary Shares (ADS) program. The company's ordinary shares will continue trading on the NYSE and the Tel Aviv Stock Exchange (TASE) under the ticker symbol 'TEVA'... Full

 

 

What's the Latest with the Trump Admin's Promise on Lower Drug Prices in Medicaid?

(9/14, Sydney Lupkin, NPR) ...NPR pharmaceuticals correspondent Sydney Lupkin has been tracking the president's plan for drug prices in Medicaid, which covers 66 million Americans who are low-income or have disabilities, and she joins us now with an update... Full

 

Trump's Drug-Price Deals Face Scrutiny at Nomination Hearing for RFK Jr.'s No. 2

(9/15, Carmen Paun, Politico) ...Chris Klomp's nomination hearing Tuesday to serve as Robert F. Kennedy Jr.'s No. 2 at the Health Department is expected to feature a proxy fight over President Donald Trump's drug-price deals...Democrats say the administration's refusal to disclose the deals' terms suggests they aren't as great as advertised. They plan to make the case at the hearing, a Senate Democratic aide granted anonymity to speak candidly, told POLITICO... Full

 

Big Pharma's Patent Monopoly Is Stealing Your Next Paycheck — and Driving up Costs

(9/12, David Marin, James Gelfand, Washington Examiner) ...Product hopping alone costs consumers $5 billion annually. Patent thickets cost $16 billion in a single year on just five drugs. These are just some examples of patent system is abused...Lawmakers are getting wise to these schemes. Several bipartisan proposals have been introduced in Congress that close the loopholes and address extended exclusivity periods for biologics... Full

 

Biosimilars Stuck in a Rut

(9/15, Adriel Bettelheim, Axios) ...What's next: A pair of biosimilars bills in Congress could be in play after the elections. One would track with this spring's FDA changes and make an approved biosimilar substitutable for a brand-name biologic without additional studies. The second would reduce the clinical testing requirements for licensing biosimilars... Full

 

Impose Tariffs Or Fix The Oncology Drug Shortage – The US Cannot Do Both

(9/14, Vibha Ravi, Pink Sheet) ...Incentives to locally manufacture oncology generics in the US could shift the demand-supply balance and help minimize disruptions. "Nearly every pharmacy director who responded to our survey would like to see economic incentives put in place to encourage high-quality manufacturing for generic cancer medications," said Alyssa Schatz, vice president of policy & advocacy at NCCN in a statement... Sub. Req'd

 

Policy Experts Concerned Duplicate Discounts Could Hinder Medicare GLP-1 Bridge

(9/14, Gabrielle Wanneh, Inside Health Policy) ..."The issue is that 340B contract pharmacies will buy drugs at a 340B discount from the manufacture and then will receive a payment from CMS as if no discount was applied. But CMS has negotiated a steep discount with the manufacturer as well," article co-author Sayeh Nikpay, vice chair of the Minnesota Prescription Drug Affordability Board, told Inside Health Policy. "The problem is that manufacturers can't really track when they've already given out a 340B discount - if they could, they would probably exempt those prescriptions from Bridge to avoid paying a large discount on the same drug twice."... Sub. Req'd

 

U.S. Health Officials Move Quickly to Deploy Medical A.I. Despite Concerns

(9/14, Christina Jewett, The New York Times) ...The Trump administration is accelerating efforts to make artificial intelligence an integral part of medical care in the United States, throwing the resources and support of the federal government into projects that deploy A.I. agents to diagnose and prescribe treatments to patients... Sub. Req'd

 

Domestic Manufacturing Incentives Join CDER Director Mike Davis' Quality Agenda

(9/14, Maaisha Osman, Pink Sheet) ..."We are realigning incentives to support manufacturers that invest in quality and that strengthen the supply chain through domestic manufacturing," [Mike Davis, the now permanent director of the US Food and Drug Administration's Center for Drug Evaluation and Research,] said. said Sept. 14 during a PDA-FDA Joint Regulatory Conference session...Davis said the agency wants a system that is "not only compliant, but more resilient. One with better visibility, more modern manufacturing capability, stronger domestic capacity, and incentives that reward investments in quality."... Sub. Req'd

 

Health Brief: Exclusive | States Line Up for Medicaid Drug Pilot

(9/14, Megan R. Wilson, Nour Wood, The Washington Post) ...So far, seven states told us that they are actually participating in the pilot program: Alaska, Arkansas, Colorado, Indiana, Massachusetts, Oregon and Pennsylvania. Missouri said it "plans to join" the model, and it's currently working through how the MFN prices compare to "bring better value" to the state... Full

 

Drugs for Autoimmune Diseases Are Pricey. This Bill Could Switch Patients to a Cheaper One

(9/14, Ana B. Ibarra, CALmatters) ...Senate Bill 1094 by Sen. Akilah Weber Pierson, a San Diego Democrat, would allow health insurers and pharmacists to substitute a patient's brand name biologic drug with a lower cost alternative known as a biosimilar, unless a patient's doctor objects. The bill would require health insurance plans to give doctors and patients 60 days' notice before switching a medication... Full

 

 

Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder

(9/14, Contineum Therapeutics) ...Contineum Therapeutics...today announced that the MOONLIGHT-1 trial did not achieve its primary efficacy endpoint. The trial evaluated improvement from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 5 compared with placebo. JNJ-5120/PIPE-307 was well-tolerated with no new safety signals... Full

 

 

Aurobindo Pharma Gets US FDA Nod to Sell First Metered-Dose Asthma Inhaler in US

(9/15, Sheersh Kapoor, CNBC TV-18) ...The approval covers Beclomethasone Dipropionate HFA Inhalation Aerosol in 40 mcg and 80 mcg strengths. The product is a generic equivalent of QVAR Inhalation Aerosol, marketed by Teva Branded Pharmaceutical Products R&D LLC... Full

 

Generic GLP-1s Are Here (For Some)

(9/10, Scott Gavura, Science-Based Medicine) ...Earlier this year I noted that one market was about to face serious disruption: Generic semaglutide was about to arrive in Canada. Well, the generics have arrived, but GLP-1 sales continue to set new Canadian records... Full

 

When Switching to a Biosimilar Isn't The End

(9/15, Axios) ...[A] recent Truveta Research study found more than 1 in 7 patients who opted for the biosimilar ultimately switched back to the brand-name product — and more than one-third did so within 30 days of receiving the first copycat drug...Truveta said the findings underscore the importance of monitoring biosimilar use after the drugs are dispensed and identifying where more patient education, clinician guidance or support accessing the drugs may help promote sustained biosimilar use... Full

 

Cancer Drug Shortages Continue With No Immediate Path Toward Relief

(9/14, Charles Bankhead, MedPage Today) ...When asked whether the shortage has improved or worsened since the first survey in 2023, 4% of pharmacy directors said the situation has improved and the rest said no change had occurred... Sub. Req'd

 

Mylan Facing Stern Test To Keep Delayed Humana Trial At Bay

(9/15, Dean Rudge, Generics Bulletin) ...Humana has moved to restart its generic price-fixing bellwether against Mylan and Lannett less than a week after the trial was put on hold, as the parties' dispute over the case's special discovery master has continued to escalate... Sub. Req'd

 

Former Perrigo Executive Gets Price-Fixing Case Partially Axed

(9/15, Katie Arcieri, Bloomberg Law) ...Douglas Boothe previously served as an executive vice president and general manager for a Perrigo entity. The plaintiffs failed to present evidence of his direct involvement in an unlawful conspiracy with regard to products including Adapalene cream and Bromocriptine tablets, said Judge Michael P. Shea of the US District Court for the District of Connecticut in a Sept. 11 summary judgment ruling... Full

 

 

GSK Strikes up to $750 Million Deal for Cancer-Targeting Drug

(9/15, Reuters) ...GSK, opens new tab said on Tuesday it had agreed a deal worth up to $750 million to buy a trispecific T cell-engager (TCE), a drug designed to help T-cells target cancer, from China-based biotechnology firm Chimagen Biosciences... Full

 

Lilly Cans Early Experimental Obesity Drug After 'High Bar' Not Met

(9/15, Darren Incorvaia, Fierce Biotech) ...The drug, codenamed LY4064912, "didn't meet our high bar for continued development," a Lilly spokesperson confirmed to Fierce. The drug's phase 1 trial, which enrolled 77 people, has been terminated. The trial was being run in California, Texas and Singapore, and included healthy volunteers as well as those with overweight or obesity... Full

 

 

EMA Reports on International API Inspection Sharing Effort

(9/14, Joanne S. Eglovitch, Regulatory Focus) ...A recent report from the European Medicines Agency (EMA) highlights that global regulators are strongly committed to sharing plans for good manufacturing practice (GMP) inspections of active pharmaceutical ingredient (API) suppliers yet have made only moderate progress toward sharing inspection reports in recent years. Joint inspections remain a challenging area, evidenced by a 50% decrease compared to the previous reporting period... Full

 

Note: Article links may expire over time or require a free registration. All news articles are the property of their respective publishers and copyright holders. [contextual emphasis added].

 

Teva global subscription access: registration is required to access FirstWord Pharma+ News and The Generics Bulletin. Please note you must be on the Teva Network (in a Teva location or connected via VPN) to access Teva's InfoNOW news resources. If you have any questions or issues, please email InfoNOW@tevapharm.com.

•      FirstWord Pharma+ News registration: first-time users, register here with your Teva email address. You will automatically receive a daily FirstWord Pharma+ newsletter; click on any news item to access your account.

•      Generics Bulletin, Pink Sheet, Scrip (Citeline) registration: go to the Generics Bulletin site and choose "Sign In" in the upper right-hand corner. First-time users, choose "Sign Up Here" and enter your Teva email address.